Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
AHK-Cu3 residuesAHKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Copper Tripeptide-3, Ala-His-Lys-Cu, AHK Copper
One published study. That is the entire scientific foundation for AHK-Cu, a synthetic copper tripeptide built from alanine, histidine, and lysine chelated to a copper ion. Pyo and colleagues showed in 2007 that this three-amino-acid compound stimulated hair follicle elongation at concentrations as low as 10 to the negative 12 molar [1]. The catch: that was an in vitro and ex vivo experiment, not a human trial. No animal studies exist. No pharmacokinetic data has been collected. Hair loss communities have adopted AHK-Cu anyway, mostly as a topical serum stacked with minoxidil. Injectable protocols borrow dosing from GHK-Cu by analogy, with no direct validation.
One peptide study, one cell culture, one promising result. Pyo et al. published in the Archives of Dermatological Research in 2007 [1] that AHK-Cu (also called Copper Tripeptide-3) stimulated human dermal papilla cell proliferation and hair follicle elongation at concentrations starting from 10 to the negative 12 molar. VEGF expression went up. Anti-apoptotic signaling shifted the Bcl-2/Bax ratio in favor of cell survival. Cleaved caspase-3 and PARP levels dropped. That is where the published science stops. No animal models. No dose-finding work. No human trial of any kind. AHK-Cu swaps glycine for alanine at position 1 compared to its better-known relative GHK-Cu. That single amino acid change alters the three-dimensional conformation enough to shift biological activity toward dermal papilla cells specifically. GHK-Cu has a broader profile, with data on wound healing, gene expression modulation across 4,000+ genes, and anti-inflammatory action. AHK-Cu appears more targeted, but "appears" is doing heavy lifting when the evidence base is a single in vitro paper. Community use tells a different story. Roughly 50 to 75 Reddit threads discuss AHK-Cu, mostly from hair loss forums. The standard topical protocol runs 0.5 to 1% serum applied once or twice daily for 12 to 24 weeks. Most users stack it with minoxidil, making it nearly impossible to isolate AHK-Cu's contribution. Injectable use is rare; fewer than 15 experience reports exist online. Sentiment is cautiously positive for topical, openly skeptical for injectable. The honest assessment: AHK-Cu has genuine biological plausibility and one solid in vitro study. It does not have the evidence to support confident dosing recommendations for either route.
AHK-Cu delivers a copper ion (Cu2+) directly to target cells. Copper is a cofactor for lysyl oxidase (which cross-links collagen), superoxide dismutase (antioxidant defense), and tyrosinase (melanin production). The peptide backbone of alanine, histidine, and lysine holds the copper in a coordinate bond until cellular uptake releases it. The hair-specific activity comes from dermal papilla cell stimulation. Pyo et al. [1] confirmed that AHK-Cu upregulates VEGF expression in these cells, promoting angiogenesis and nutrient delivery to hair follicles. The peptide also shifts the Bcl-2/Bax ratio toward anti-apoptotic signaling. In practical terms, cells that would otherwise enter programmed death stay alive longer. Levels of cleaved caspase-3 and PARP, two execution enzymes in the apoptosis cascade, drop measurably. In fibroblasts, AHK-Cu drives collagen I and III deposition and increases extracellular matrix protein turnover. This is where the skin rejuvenation claims come from; more collagen and elastin production translates to firmer, smoother skin over time. All of this has been demonstrated in cell cultures and ex vivo models only. The jump from "works on cells in a dish" to "works when injected or applied topically on a living person" is not guaranteed. GHK-Cu made that jump with extensive published data. AHK-Cu has not.
AHK-Cu has exactly one relevant published study, Pyo et al. 2007, which demonstrated hair follicle elongation and dermal papilla cell proliferation in an ex vivo/in vitro model. The effect was real and dose-dependent, occurring at concentrations as low as 10⁻¹² M. VEGF upregulation and anti-apoptotic signaling (Bcl-2/Bax modulation) were confirmed. But there are no in vivo animal studies, no human trials, no pharmacokinetic data, and no dose-finding studies for any route of administration. The 2025 Kuceki microneedling study (PMC11992372) used copper peptides as part of a multi-agent cocktail and can't be attributed to AHK-Cu alone.
Pyo et al. 2007, Archives of Dermatological Research (PMID 17703734): ex vivo human hair follicle elongation and in vitro DPC proliferation
Single study, in vitro/ex vivo only, no animal models, no human trials, no PK data. All injectable dosing is analogical from GHK-Cu. The structural similarity to GHK-Cu is suggestive but not validated for systemic use.
Community interest is growing, especially in hair loss communities, but experience is dominated by topical use. Most users stack AHK-Cu with minoxidil or GHK-Cu. Injectable use is rare: maybe a dozen Reddit reports total. Topical users report modest hair improvements at 3-6 months but acknowledge it's hard to isolate AHK-Cu's contribution in stacked protocols. Sentiment is cautiously positive for topical, skeptical for injectable.
Science and community agree AHK-Cu has hair follicle activity, but diverge sharply on routes. The published study used cell cultures and ex vivo follicles: there's no bridge to the topical or injectable concentrations the community uses. Community topical protocols are reasonable extrapolations from cosmetic ingredient usage. Injectable protocols have no scientific basis specific to AHK-Cu.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 250mcg | Daily |
| Aggressive | 500mcg | Daily |
Reconstitution math for injectable use: a 5 mg vial with 1 mL bacteriostatic water gives you 5,000 mcg/mL. On an insulin syringe, 2 units equals 100 mcg (beginner dose) and 5 units equals 250 mcg (moderate dose). A 5 mg vial lasts 20 days at the moderate dose. With a 50 mg vial and 2 mL bacteriostatic water, you get 25,000 mcg/mL; 1 unit equals 250 mcg. The powder should be blue-green. If it's white or colorless, the copper chelation probably didn't happen and you're injecting a plain tripeptide. Always check the Certificate of Analysis for HPLC purity and amino acid composition. Most AHK-Cu on the market is cosmetic-grade. If you're injecting, confirm the vendor offers injectable-grade product with endotoxin testing. This matters more than price. Don't apply AHK-Cu right after a vitamin C serum. The low pH destroys the copper complex on contact. Split them AM and PM, or wait at least 30 minutes between applications. Store reconstituted vials at 2 to 8 degrees Celsius. Use within 2 to 3 weeks. Discard if the solution changes color or shows particles.
For injectable use, cycle 8-12 weeks on with a 4-week break. Topical formulations (0.5-1%) can be applied continuously without cycling. Hair growth protocols may require 12-24 weeks for meaningful results.
The 12 on / 4 off cycling protocol for injectable AHK-Cu is conservative guidance based on general copper peptide principles, not AHK-Cu-specific data. The rationale is to allow a wash-out period to monitor for copper accumulation and assess response. At 100-500 mcg/day, the systemic copper load is small (copper content of the peptide is a fraction of the total mass), but no long-term safety data exists to confirm continuous use is safe. Topical AHK-Cu doesn't require cycling: systemic absorption from skin application is minimal.
Or use the universal Peptide Calculator for any peptide.
Expected: Reduced shedding by week 6-8, possible new vellus hair by week 8-12, measurable improvement in hair density by week 16-24. Results are modest and variable.
Monitor: Photograph scalp under consistent lighting monthly. Track daily hair loss count in weeks 1-8 to distinguish initial shedding from ongoing loss.
Reconstitute a 5 mg vial by adding 1 mL of bacteriostatic water. Direct the stream against the glass wall, not the powder cake. Let it dissolve without shaking (2 to 3 minutes). This gives you a concentration of 5,000 mcg per mL. The solution should have a light blue tint.
Draw your dose using an insulin syringe (29 to 31 gauge needle). For 100 mcg (beginner), draw to the 2 unit mark. For 250 mcg (moderate), draw to the 5 unit mark. For 500 mcg (aggressive), draw to the 10 unit mark.
For hair growth, inject subcutaneously near the scalp or into the abdomen for systemic distribution. For skin rejuvenation, the abdomen or thigh works well.
Pinch a fold of skin, insert the needle at a 45-degree angle, and inject slowly. Release and apply gentle pressure with a cotton pad.
Store the reconstituted vial at 2 to 8 degrees Celsius between uses.
For topical use: apply 4 to 6 drops of 0.5 to 1% AHK-Cu serum to clean, dry skin or scalp once or twice daily. Massage gently and allow 15 to 30 minutes for absorption before layering other products. Evening application is preferred if using vitamin C in the morning.
0.5-1% concentration in serum, 1-2x daily. Not directly comparable to injectable mcg doses.
Adequate penetration to dermal papilla cells has been demonstrated for copper peptides at these concentrations. This is the route supported by the published research model.
Same serum concentration, but penetration is significantly enhanced. Effective dose to follicles may be higher.
The 2025 Kuceki study (PMC11992372) used microneedling with copper peptides + other agents and saw strong regrowth. Don't microneedle more than 1x/week.
100-500 mcg/day: doses are borrowed from GHK-Cu protocols. No AHK-Cu PK data to validate.
Most AHK-Cu available is cosmetic-grade and not intended for injection. If choosing this route, use only injectable-grade product with endotoxin testing.
Complementary copper peptides: GHK-Cu provides broader regenerative and gene-modulatory effects, AHK-Cu adds targeted dermal papilla stimulation. Often co-formulated in topical serums.
Apply both topically: GHK-Cu first, AHK-Cu second, or use a combined formulation
Different mechanisms (potassium channel opening vs. VEGF/DPC stimulation). The most common stack in hair loss communities. Compatible but apply at different times to avoid dilution.
Minoxidil AM, AHK-Cu PM: or vice versa. Don't mix in the same application
Some users combine injectable BPC-157 for its angiogenic and healing properties with topical AHK-Cu for hair support. Theoretical synergy via VEGF pathway convergence.
Zinc competes with copper at transport sites. Chronic high zinc intake depletes copper stores and could reduce AHK-Cu effectiveness.
These drugs specifically bind and remove copper: they'll strip the Cu²⁺ from AHK-Cu and neutralize it completely.
Do not combineAscorbic acid at pH 2.5-3.5 reduces Cu²⁺ to Cu⁺, irreversibly breaking the copper-peptide bond. Not a theoretical concern: it's basic coordination chemistry. Separate by 30+ minutes or use AM/PM split.
Pricing updated 2026-04-09
The biggest concern with AHK-Cu is not a specific adverse event. It is the near-total absence of safety data. One in vitro study (Pyo et al. 2007)[1] and roughly 50 to 75 community reports form the entire safety picture. No formal adverse event tracking exists for this compound in any route of administration. For injectable users, copper accumulation is the primary theoretical risk. AHK-Cu delivers copper systemically when injected at 100 to 500 mcg daily. While these doses contribute far less copper than a typical diet provides, no long-term safety data confirms that daily subcutaneous copper peptide delivery is benign. Early warning signs of copper excess include metallic taste, GI symptoms (nausea, abdominal pain), persistent skin discoloration at injection sites, and unexplained fatigue. Serum copper and ceruloplasmin monitoring at baseline and every 8 weeks is recommended for anyone injecting. Injection site reactions are expected with any subcutaneous peptide. Redness, swelling, and mild pain at the site are the most commonly reported issues in the small injectable user base. Temporary hair shedding in the first 4 to 6 weeks is reported in rare cases in the community. This reflects dormant follicles being pushed into a new growth cycle, the same phenomenon seen with minoxidil initiation. It typically resolves by week 6 to 8. If heavy shedding continues past week 8 or comes with scalp irritation, discontinue use. Topical application carries lower risk. Mild redness or irritation at the application site is occasional. Contact sensitivity to the copper compound is rare but possible. Vitamin C interaction is real and specific. Ascorbic acid at pH 2.5 to 3.5 reduces Cu2+ to Cu+, breaking the coordinate bond that makes AHK-Cu biologically active. Separate application by at least 30 minutes. Contraindications: Wilson's disease or any copper metabolism disorder, Menkes disease, active skin infection at the site, pregnancy or breastfeeding (no safety data), known copper hypersensitivity, and concurrent high-dose oral copper supplementation. When to seek medical attention: persistent metallic taste, skin discoloration that doesn't resolve, GI symptoms, or any unexplained systemic effects. There is no safety database to reference for AHK-Cu, so err on the side of caution and discontinue at the first sign of anything unexpected.
Verify AHK-Cu dosing and safety with a second opinion
AHK-Cu is available primarily as cosmetic-grade powder from ingredient suppliers, not pharmaceutical manufacturers. Purity claims of 99% are common but third-party verification varies by vendor. The compound is relatively simple (tripeptide + copper ion) compared to larger peptides, reducing, but not eliminating, the risk of degraded or mislabeled product.
| Test | When | Target |
|---|---|---|
| Serum copper | Baseline and every 8 weeks (injectable users only) | 70-140 mcg/dL (normal adult range) |
| Ceruloplasmin | Baseline (injectable users only) | 20-50 mg/dL |
| Scalp photography | Baseline, week 8, week 16, week 24 | — |
AHK-Cu delivers copper systemically when injected. While daily doses of 100-500 mcg are far below toxic thresholds, monitoring confirms no unexpected accumulation.
Low ceruloplasmin may indicate impaired copper metabolism (Wilson's disease screening). Run before starting any copper peptide injections.
Objective tracking of hair density changes. Use consistent lighting, angle, and camera distance. Subjective assessment is unreliable for slow-onset changes.
Cellular signaling begins. No visible changes expected. Some users may notice temporary increased shedding as dormant follicles re-enter the growth cycle.
Early improvements in skin hydration and texture. Fine vellus hairs may appear at thinning areas.
Noticeable improvements in skin firmness. Hair shedding normalizes. New hair growth becomes more visible.
Peak results for hair regrowth protocols. Meaningful increase in hair density and thickness. Skin shows reduced fine lines.
Weeks 1 to 4, Adjustment Phase. Molecular activity starts at the cellular level but nothing is visible yet. VEGF upregulation and dermal papilla cell stimulation begin based on what the in vitro data predicts. Rare cases of increased hair shedding have been reported during this window, reflecting dormant follicles being pushed into a new growth cycle. Some scalp tingling or warmth after topical application is normal. Most users feel like the product isn't doing anything. Weeks 4 to 8, Early Response. If follicles shifted from telogen to anagen in the first month, new growth should be initiating below the skin surface. No published timeline data exists for AHK-Cu specifically. Community users notice shedding starting to taper off. A few report fine vellus hairs appearing at thinning spots. Skin texture improvements show up for facial application users. Occasional dryness can happen from over-application. Weeks 8 to 16, Visible Changes Begin. Based on hair follicle biology (not AHK-Cu data), new anagen hairs initiated early in the protocol should be emerging and thickening from vellus to intermediate diameter. Users who respond see new growth becoming visible. Skin users report smoother texture and softer fine lines. Non-responders see no change at all by this point. Weeks 16 to 24, Peak Protocol Results. A full hair cycle takes 4 to 6 months. Any follicle activation driven by AHK-Cu should be producing visible terminal hair growth by now. The best results land in this window: increased hair density and thickness in responders, stabilized skin improvements. Community consensus holds that if nothing has changed by week 20, AHK-Cu likely isn't going to work for you.
Cellular signaling initiates. DPC stimulation and VEGF upregulation occur at the molecular level (based on in vitro data). No visible changes expected.
Temporary increased shedding is the most common report. Some scalp tingling or warmth after topical application. Most users feel like nothing is happening.
If follicles are being shifted from telogen to anagen, new growth should be initiating beneath the surface. No published timeline data specific to AHK-Cu.
Shedding begins to normalize. Some users notice improved scalp condition and skin texture. A few report fine vellus hairs appearing in thinning areas.
Based on hair follicle biology (not AHK-Cu data), anagen hairs initiated in weeks 1-4 should be emerging and transitioning from vellus to intermediate thickness.
Users who respond see new hair growth becoming visible. Skin users report smoother texture and reduced fine lines. Non-responders see no change.
Full hair cycle requires 4-6 months. Any AHK-Cu-driven follicle activation should be producing visible terminal hair growth by this point.
Best results are reported in this window: increased hair density and thickness in responders. Skin improvements stabilize. Community consensus is that if nothing has changed by week 20, AHK-Cu likely isn't working for you.
Source: Estimated from structural analogy to GHK-Cu; no direct pharmacokinetic studies published for AHK-Cu.
Loading the interactive decay curve.
AHK-Cu carries a research-only regulatory status. It has no FDA approval, no investigational new drug application on record, and no monograph in any pharmacopeia. The compound is sold as a cosmetic ingredient (Copper Tripeptide-3) or as a research chemical. Most commercially available AHK-Cu is manufactured to cosmetic-grade standards. Products labeled "injectable grade" from peptide vendors exist but are not regulated as drugs. No compounding pharmacy formulation has been established for AHK-Cu, unlike GHK-Cu which some compounding pharmacies carry. AHK-Cu does not appear on the WADA prohibited list as of 2026. Athletes should verify current status before use. This content is for informational and educational purposes only. It does not constitute medical advice. AHK-Cu is not approved for any medical use. Consult a qualified healthcare provider before using any research compound. Peptide Schedule does not sell peptides or endorse any specific vendor.
Peptide Schedule Research TeamReviewed Apr 20264 Citations
